ExSight Ventures
Venture capitalNew York · Pre-Seed–Series B · 4 people tracked
Investment thesis
ExSight Ventures invests in early-stage companies developing breakthrough technologies to aid, diagnose, and treat people affected by vision diseases. The firm leverages deep ophthalmology domain expertise—led by two retinal surgeons—as an advantage over generalist investors, treating its focused specialization as a form of validation for a company's technology. It emphasizes capital efficiency, investing predominantly in technology development at the pre-seed through Series B stages. The firm argues that diversification is best achieved across focused managers rather than across holdings, and points to macro trends such as an aging population, rising diabetes, and a growing global middle class as drivers of demand for eye care innovation.
Source: firm website, verified Aug 3, 2026.
Team · 4 people
from the firm's websiteWhat they invest in
from 14 of 21 portfolio companiesBiotech ×11Healthtech ×7Medical Devices ×7Media & Entertainment ×2AI & Machine Learning ×1Hardware ×1Robotics ×1
HQs:United States×10United Kingdom×1
Investments · 21 tracked
founders shown can be your intro pathBy year:2025 · 12019 · 12017 · 13 dated
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder & Chief Scientific Officer)David Esposito(Executive Officer, Director)Constance Chang(Executive Officer)John K Freshley(Executive Officer, Director)Jeffrey A Jamison(Executive Officer)David N Zacks(Executive Officer, Director)
Co-investorsInvest MichiganNovartis Venture FundVisionary VenturesBios PartnersInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more
Trefoil Therapeutics is a clinical-stage biotechnology company developing therapeutic agents for corneal diseases.
BiotechHealthtechMedical DevicesSan Diego, US
David Eveleth(Executive Officer, Director)Schalon Newton(Executive Officer)
BoardChristy Shaffer(Director)inRalph Bradshaw(Director)
Co-investorsSolasta VenturesAccess BiotechnologyBios PartnersCorrelation VenturesFemHealth VenturesHatteras Venture Partners+2 more
HealthtechIrvine, US
JAMES TAYLOR(Executive Officer)IRVING ROBERT ARMSTRONG(Executive Officer)ROBERT SHIMIZU(Executive Officer)NARESH MANDAVA(Director)
BoardAKITERU FURUKAWA(Director)CLAUDE BENEDICT(Director)
BiotechSan Diego, US
Arthur T Suckow(Executive Officer)Arthur Suckow, Ph.D.(Founder)in
Co-investorsAccess BiotechnologyRA Capital
Implant-free, minimally invasive glaucoma surgery (MIGS) creating microscopic channels in the eye to lower intraocular pressure.
Reinventing the eye exam with binocular OCT-based diagnostic technology.
Torrance, US
Alexander Walsh(Executive Officer, Director)Patrick Welsh(Director)Patrick Walsh(Director)Paul Updike(Executive Officer)Patrick C. Walsh(Director)Richard Castro(Executive Officer)
Co-investorsACTAI VenturesAdjuvoAlliance VenturesAppian Capital AdvisoryArkam VenturesAsia2G Capital+49 more
Horizon Surgical Systems develops assistive microsurgical robotics with real-time 3D multimodal imaging and machine learning to support surgeons performing cataract surgery.
AI & Machine LearningMedical DevicesRobotics
Springer is an academic and scientific publisher with a portfolio of over 2,700 journals and more than 220,000 books, serving researchers, authors, readers, and institutions worldwide.
Media & Entertainment
Co-investorsChanzo Capital
LensGen is an ophthalmic medical device company that has developed Juvene, a curvature-changing fluid-optic intraocular lens designed to treat cataracts and presbyopia.
BiotechHardwareHealthtechMedical DevicesIrvine, US
Ramgopal Rao(Founder & Chief Executive Officer)Shivbir Grewal(Director)
BoardAkiteru Furukawa(Director)Michael Colaco(Director)
Co-investorsLightstone Ventures
Novai develops DARC technology for early detection and intervention of eye and brain diseases, aiming to reduce blindness and disability.
BiotechHealthtechMedical DevicesReading, GB
Co-investorsAnglia Capital GroupZinc
Co-investorsClarendon Fund Managers Ltd.Visionary Ventures
First-in-class optogenetic therapy for retinal diseases; acquired by Allergan.
BiotechAnn Arbor, US
Sean Ainsworth(Executive Officer, Director)
BoardTerry Cross(Director)Kenneth Kousky(Director)Cam Gallagher(Director)George Lasezkay(Director)
Co-investorsBoston Harbor AngelsGREAT LAKES BAY VENTURE
BiotechSpringfield, US
Ramanath Bhandari(Executive Officer)Jeff Olson(Director)
BoardRam Palanki(Director)
BiotechHealthtech
Co-investorsClal Biotechnology IndustriesLongitude CapitalTachyon VenturesThe Column Group
Valitor develops bioactive molecule therapies using a multivalent biopolymer technology platform to create long-acting treatments for ophthalmologic diseases, with its lead candidate VLTR-559 targeting wet age-related macular degeneration.
BiotechMedical DevicesBerkeley, US
Wesley Jackson(President, Chief Scientific Officer & Member of the Board)Gregory D. Kunst(Chief Executive Officer)Carole H Bellis(Executive Officer)Kevin E Healy(Director)Jackson M Wesley(Executive Officer, Director)
BoardDrew Lanza(Director)in
Co-investorsAngel Physicians FundBerkeley CatalystFirst Spark Ventures, LlcPandect Bioventures
Exits · 2
IPOs and acquisitions across the tracked portfolioDTx Pharmaacq. by NovartisRetroSense Therapeuticsacq. by Allergan
Portfolio news
latest coverage across their companiesTrefoil Therapeutics · hatterasvp.com · Jan 9, 2026
RevOpsis Therapeutics · finsmes.com · Sep 16, 2025
Frequently asked questions
- How many investments has ExSight Ventures made?
- ExSight Ventures has 20 tracked investments, 2 of which have exited via acquisition or IPO.
- What stage does ExSight Ventures invest at?
- ExSight Ventures invests at the Pre-Seed, Seed, Series A, Series B stages.
- What sectors does ExSight Ventures focus on?
- ExSight Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is ExSight Ventures located?
- ExSight Ventures is headquartered in New York.
- Who does ExSight Ventures co-invest with?
- ExSight Ventures most often shares deals with Visionary Ventures, First Spark Ventures, Llc, Lightstone Ventures, among 22 tracked co-investors.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
Panacea Venture is a global investment firm, spun out from Kleiner Perkins, focused on life sciences and healthcare innovation. It invests across geographies and stages, from company formation through expansion and public markets.
Lang Sheng Investment (朗盛投资) is a leading Chinese investment firm focused on the large healthcare sector, with experience in screening, investing in, and supporting medical and health companies.